Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Tools to improve the outcomes of patients with CLL affected by COVID-19

Antonio Cuneo • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia Antibodies Molnupiravir Nirmatrelvir Ritonavir

Antonio Cuneo, MD, St. Anna University Hospital, Ferrara, Italy, highlights the importance of COVID-19 vaccination for patients with chronic lymphocytic leukemia (CLL) and everyone in their day-to-day environment. Prophylaxis during treatment and immediate intervention upon the observation of COVID-19 symptoms is also recommended to prevent infection. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Antonio Cuneo

1:25
The management of CLL in Italy
Antonio Cuneo • 7 Oct 2022
1:09
The impact of complex karyotype on treatment efficacy and prognosis in CLL
Antonio Cuneo • 7 Oct 2022
1:45
The importance of real-world data in CLL & efficacy of BTK and Bcl-2 inhibitors in the real world
Antonio Cuneo • 7 Oct 2022
2:12
The impact of genetic abnormalities on treatment decisions in CLL
Antonio Cuneo • 7 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals